Glenmede Investment Management, LP Halozyme Therapeutics, Inc. Transaction History
Glenmede Investment Management, LP
- $20 Billion
- Q3 2025
A detailed history of Glenmede Investment Management, LP transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Glenmede Investment Management, LP holds 175,687 shares of HALO stock, worth $12.5 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
175,687
Previous 169,291
3.78%
Holding current value
$12.5 Million
Previous $8.81 Billion
99.85%
% of portfolio
0.06%
Previous 0.04%
Shares
2 transactions
Others Institutions Holding HALO
# of Institutions
648Shares Held
156MCall Options Held
408KPut Options Held
366K-
Dld Asset Management, LP New York, NY30MShares$2.14 Billion10.67% of portfolio
-
Black Rock Inc. New York, NY17.6MShares$1.25 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$828 Million0.01% of portfolio
-
State Street Corp Boston, MA5.02MShares$357 Million0.01% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA3.29MShares$234 Million0.16% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.92B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...